Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Hit-to-lead optimization of 2-aminoquinazolines as anti-microbial agents against Leishmania donovani.
Das N, Roy J, Patra B, Saunders E, Sarkar D, Goon S, Sinha BP, Roy S, Roy S, Sarif J, Bandopadhyay P, Barik S, Mukherjee S, McNamara N, Varghese S, Simpson K, Baell J, McConville M, Ganguly D, Talukdar A. Das N, et al. Among authors: sarif j. Eur J Med Chem. 2024 Apr 5;269:116256. doi: 10.1016/j.ejmech.2024.116256. Epub 2024 Feb 27. Eur J Med Chem. 2024. PMID: 38461679
Clinical Trial Subgroup Analyses to Investigate Clinical and Immunological Outcomes of Convalescent Plasma Therapy in Severe COVID-19.
Raychaudhuri D, Bandopadhyay P, D'Rozario R, Sarif J, Ray Y, Paul SR, Singh P, Chaudhuri K, Bhaduri R, Pandey R, Bhattacharya P, Sengupta S, Chatterjee S, Ganguly D. Raychaudhuri D, et al. Among authors: sarif j. Mayo Clin Proc Innov Qual Outcomes. 2022 Dec;6(6):511-524. doi: 10.1016/j.mayocpiqo.2022.09.001. Epub 2022 Sep 14. Mayo Clin Proc Innov Qual Outcomes. 2022. PMID: 36117954 Free PMC article.
A phase 2 single center open label randomised control trial for convalescent plasma therapy in patients with severe COVID-19.
Ray Y, Paul SR, Bandopadhyay P, D'Rozario R, Sarif J, Raychaudhuri D, Bhowmik D, Lahiri A, Vasudevan JS, Maurya R, Kanakan A, Sharma S, Kumar M, Singh P, Roy R, Chaudhury K, Maiti R, Bagchi S, Maiti A, Perwez MM, Mondal A, Tewari A, Mandal S, Roy A, Saha M, Biswas D, Maiti C, Bhaduri R, Chakraborty S, Sarkar BS, Haldar A, Saha B, Sengupta S, Pandey R, Chatterjee S, Bhattacharya P, Paul S, Ganguly D. Ray Y, et al. Among authors: sarif j. Nat Commun. 2022 Jan 19;13(1):383. doi: 10.1038/s41467-022-28064-7. Nat Commun. 2022. PMID: 35046397 Free PMC article. Clinical Trial.
Plasma Gradient of Soluble Urokinase-Type Plasminogen Activator Receptor Is Linked to Pathogenic Plasma Proteome and Immune Transcriptome and Stratifies Outcomes in Severe COVID-19.
Sarif J, Raychaudhuri D, D'Rozario R, Bandopadhyay P, Singh P, Mehta P, Hoque MA, Sinha BP, Kushwaha M, Sahni S, Devi P, Chattopadhyay P, Paul SR, Ray Y, Chaudhuri K, Banerjee S, Majumdar D, Saha B, Sarkar BS, Bhattacharya P, Chatterjee S, Paul S, Ghosh P, Pandey R, Sengupta S, Ganguly D. Sarif J, et al. Front Immunol. 2021 Oct 28;12:738093. doi: 10.3389/fimmu.2021.738093. eCollection 2021. Front Immunol. 2021. PMID: 34777349 Free PMC article.
Nature and Dimensions of Systemic Hyperinflammation and its Attenuation by Convalescent Plasma in Severe COVID-19.
Bandopadhyay P, D'Rozario R, Lahiri A, Sarif J, Ray Y, Paul SR, Roy R, Maiti R, Chaudhuri K, Bagchi S, Maiti A, Perwez MM, Sarkar BS, Roy D, Chakraborty R, Vasudevan JS, Sharma S, Biswas D, Maiti C, Saha B, Bhattacharya P, Pandey R, Chatterjee S, Paul S, Ganguly D. Bandopadhyay P, et al. Among authors: sarif j. J Infect Dis. 2021 Aug 16;224(4):565-574. doi: 10.1093/infdis/jiab010. J Infect Dis. 2021. PMID: 34398242 Free PMC article. Clinical Trial.
12 results